Thomas Milz

Director
Strategic Business Development
& Market Access

We stand for exchanging ideas and building connections. For the benefit of our patients. Each and every day.

We are your strategic partner.

 BUSINESS DEVELOPMENT

What sets us apart: we are a unique cooperation partner

APONTIS PHARMA – the name is new but the high quality standards have stayed the same for decades. We are a well-established pharmaceutical company actively involved in promoting and marketing innovative and ethical drugs in cooperation with general practitioners and primary health care providers. Thanks to our excellent sales force team, APONTIS PHARMA is the partner of choice for many big pharmaceutical companies. Long-standing and trusting partnerships are the key to jointly achieving success.
Our portfolio  covers not only our own products but also strategic partnerships. In this respect our key focus is on the following markets: cardiovascular diseases, respiratory diseases, diabetes, and dermatology. A holistic growth strategy enables APONTIS PHARMA to add other drugs to its portfolio. In this regard our offering includes in-licensing and promoting in already existing product areas as well as for new indications, for example for biologics and in the fields of oncology and immunology.

APONTIS PHARMA enjoys a high reputation with prescribers and payers in Germany – thanks to our well-established and long-standing access to around 24,000 doctors.

Product cooperations in the German market:

2009Jalra® & Icandra®
2013Tonotec®
2015Caramlo®
2016Ulunar®
2017Iltria®
2017Biramlo®
2019Atorimib®
2019LosAmlo®
2019Tonotec®HCT
CONTACT BUSINESS DEVELOPMENT

APONTIS PHARMA enjoys a high reputation as an efficient, reliable, and competent partner.

Thomas Milz

Director
Strategic Business Development
& Market Access

Do you like our partnership-based approach to thought and action and want to work together with us? Then please feel free to contact us!

For press enquiries, job applications or questions about our products or training materials, please use the respective contact information.